Arrail Group Limited (HKG:6639)
Hong Kong · Delayed Price · Currency is HKD 2.600
-0.110 (-4.06%)
Aug 1, 2025, 4:08 PM HKT
Ligand Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Arrail Group had annual revenue of 1.69B CNY, down -3.29%. Arrail Group had revenue of 800.92M in the half year ending March 31, 2025, with 14.06% growth.
Revenue
1.69B CNY
Revenue Growth
-3.29%
P/S Ratio
0.81
Revenue / Employee
542.72K CNY
Employees
3,111
Market Cap
1.46B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.69B | -57.39M | -3.29% |
| Mar 31, 2024 | 1.75B | 272.04M | 18.46% |
| Mar 31, 2023 | 1.47B | -149.81M | -9.23% |
| Mar 31, 2022 | 1.62B | 108.43M | 7.16% |
| Mar 31, 2021 | 1.52B | 415.26M | 37.76% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |